文摘
摘要目的:探讨脑脊液(CSF)之间的关联生物标志物的阿尔茨海默病(AD) (Aβ1-42,p-tau181年)、神经精神症状(NPS)和认知功能的疾病谱系。
背景:神经精神症状往往是广告的早期表现。之前的研究使用CSF Aβ和NPS p-tau表明AD病理的影响是由认知障碍。NPS在疾病的原因连续知之甚少。
设计/方法:这个样本包括1772名参与者的国家老年痴呆症协调中心(NACC)脑脊液生物标志物数据可用。缺乏标准化NACC CSF分析。CSF Aβ1-42,p-tau181年,t-tau测量使用ELISA (n = 276), Luminex (n = 680)、和Lumipulse (n = 816)。NPS测量使用神经库存调查问卷(NPI-Q)。因子分析减少NPI-Q项目到一个单一的因素。MMSE估计全球认知。中介模型使用Kemeny估计协方差矩阵在结构方程模型框架中,控制了年龄、教育、性别、APOEɛ4,脑脊液化验方法。模型在整个样本和排除痴呆。
结果:示例包括老年人(米= 71.6,SD= 8.98;896年,50.6%的女性;590年,33%痴呆)那些白人(n= 1600,90.3%)。降低脑脊液Aβ1-42预测高NPI-Q分数,βz=−0.242,95%置信区间CI: 0.312−−0.172,部分由MMSE分数,(即标准化的间接影响z)=−0.098,95%置信区间CI: 0.123−−0.073。更高的CSF p-tau181年预测高NPI-Q分数,βz= 0.127,95% CI: 0.044, 0.210,部分由MMSE评分,即z= 0.041,95% CI: 0.021, 0.061。CSF t-tau没有预测NPI-Q或MMSE分数。在那些没有痴呆,效果减弱,只有CSF Aβ1-42预测高NPI-Q分数,βz=−0.130,95%置信区间CI: 0.248−−0.013,部分由MMSE评分,即z=−0.022,95%置信区间CI: 0.036−−0.007。
结论:NPS可能继发于AD病理和认知障碍。然而,AD病理可能扮演的角色的表现NPS在疾病早期阶段。
披露:沃尔什先生没有披露。弗兰克博士没有披露。赫尔利博士已经收到个人赔偿作为尼尔森公司的一名雇员。赫尔利博士已经收到个人赔偿作为耶鲁大学的一名员工。赫尔利博士已经收到个人薪酬在500 - 4999美元的范围为iOpening企业担任顾问。Kaj Blennow已收到个人薪酬在500 - 4999美元的范围作为顾问生原体,轴突,JOMDD,罗氏公司,西门子。Kaj Blennow已收到个人薪酬在500 - 4999美元的范围为在科学咨询服务或数据安全监测委员会诺华,朱利叶斯临床。Kaj Blennow已收到个人薪酬在500 - 4999美元的范围服务扬声器MagQu管理局。Henrik Zetterberg已收到个人薪酬在500 - 4999美元的范围为罗氏公司担任顾问。Henrik Zetterberg已收到个人补偿的范围0 - 499美元为Abbvie担任顾问。Henrik Zetterberg已收到个人补偿的范围0 - 499美元为Acumen担任顾问。 Henrik Zetterberg has received personal compensation in the range of $0-$499 for serving as a Consultant for AlzPATH. Henrik Zetterberg has received personal compensation in the range of $0-$499 for serving as a Consultant for Annexon. Henrik Zetterberg has received personal compensation in the range of $0-$499 for serving as a Consultant for Apellis. Henrik Zetterberg has received personal compensation in the range of $0-$499 for serving as a Consultant for Fujirebio. Henrik Zetterberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Siemens Healthineers. Henrik Zetterberg has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Henrik Zetterberg has stock in Brain Biomarker Solutions. Yorghos Tripodis, 5406 has nothing to disclose. Brett Martin has nothing to disclose. Dr. Weller has nothing to disclose. Prof. Qui has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for IQVIA. The institution of Prof. Qui has received research support from NIH. Dr. McKee has nothing to disclose. Dr. Stein has nothing to disclose. Robert Stern, PhD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. The institution of Robert Stern, PhD has received research support from Eisai. The institution of Robert Stern, PhD has received research support from Lilly. The institution of Robert Stern, PhD has received research support from ATRI/NIA. Robert Stern, PhD has received publishing royalties from a publication relating to health care. Robert Stern, PhD has a non-compensated relationship as a Member with NFLPA Mackey-White Committee that is relevant to AAN interests or activities. The institution of Dr. Mez has received research support from NIH, DOD. The institution of Michael Alosco, PHD has received research support from NIH.
